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Pacemaker Systems . . .* 
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Bronx, New York 
The management of tachyarrhythmias as well as brady- 
arrhythmias has been a goal of cardiac pacing for the past 20 
years. The success of programmed cardiac electrical stimu- 
lation to begin, end and control the evolution and duration of 
a tachyarrhythmia has continued to encourage the hope that 
an implanted device providing such stimulation could be 
used therapeutically. Despite intensive efforts, few patients 
have been definitively treated by pacing alone, and of those 
who have, most have been treated for supraventricular 
arrhythmias. Ventricular tachyarrhythmias, which are far 
more severe, disabling and lethal, have remained largely 
unmanaged by cardiac pacing. 
Role of antitachycardia pacing. Pacing can produce one 
of four results: the tachyarrhythmia may be terminated, 
there may be no therapeutic effect, the tachycardia may be 
changed in rate or focus or from a monomorphic to a 
polymorphic configuration or vice versa or the tachycardia 
may be accelerated to a more rapid rate or to ventricular 
fibrillation. The last possibility, even after extensive clinical 
testing and multiple successful tachycardia terminations 
(usually as many as loo), has virtually stopped the use of 
ventricular antitachycardia pacing in all circumstances ex- 
cept in the presence of the automatic implantable cardio- 
verter defibrillator (AICD). This device can terminate ven- 
tricular tachycardia or fibrillation by a shock several 
thousand times larger, and substantially more disabling and 
uncomfortable, than the stimulus delivered by a pacemaker. 
Why consider pacing when it does not terminate a tachy- 
arrhythmia as effectively as the AICD, which can stop 
ventricular tachycardia, against which a pacemaker may be 
effective, and ventricular fibrillation, against which it is 
ineffective? Each AICD shock is painful; if the patient is 
awake, it stops coordinated activity and may be a potential 
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hazard if she or he is operating a motor vehicle or even 
holding a pot of boiling water. The AICD continues to have 
a short life span, which is further shortened with each shock 
and each evaluation of battery status. The delivery of a 
shock may result in termination of ventricular tachyfibrilla- 
tion and may yield bradycardia or asystole of significant 
duration (caused by sinus arrest with failure of prompt nodal 
escape), sinus bradycardia or complete heart block. In each 
instance, a pacemaker is required. Antitachycardia pace- 
makers are useful because, in some patients, they can 
terminate a tachycardia promptly, painlessly and very effec- 
tively-but not reliably. Thus, some patients may need 
subsequent treatment for the complication of tachycardia 
acceleration, which is performed very well by the AICD. 
Problems with combined AICD and pacemaker. At 
present, and for the immediate future, the AICD and pace- 
maker are and will be independent devices despite medical 
and industrial awareness that they will commonly be used 
simultaneously in the same patient. One third of the patients 
at this institution with an AICD have a pacemaker implanted 
as well. Single devices in which a pacemaker and an AICD 
are combined and their interaction satisfactorily managed 
are not available but are under development by several 
manufacturers. It is not yet clear what kind of pacemaker 
will be incorporated in these early combined devices. If a 
simple single chamber unit is needed for rate support alone, 
independent antitachycardia devices will still be required. If 
a more complex situation exists, then problems with device 
interaction may persist. 
A pacemaker may trigger an AICD discharge during 
magnet application with both pacemaker stimuli and spon- 
taneous QRS complexes counted, or the two pulse genera- 
tors may be anatomically so close that magnet application 
affects both. Unipolar pacing may also produce a stimulus 
large enough to be sensed by the AICD, which may count 
both stimulus and consequent cardiac depolarization. Even 
bipolar stimuli may, if not carefully evaluated, reach the 
level of being sensed by the AICD circuit. Conversely, a 
pacemaker that is unable to sense ventricular fibrillation may 
continue emitting stimuli at its escape rate of 60 to 80 beats/ 
min and inhibit the output of the AICD. Each of these 
circumstances can cause a false AICD discharge or failure to 
discharge when needed. Another possibility is that an AICD 
discharge, whether appropriate or not, will destroy the 
pacemaker. This possibility cannot be eliminated until a 
combined device consistently protects its pacemaker com- 
ponent. 
Even the volume of hardware and the inevitable compro- 
mises made because of the need to accomodate multiple 
pieces can create problems. Pacemaker leads, AICD sensing 
leads, patch leads, the pacemaker itself and the AICD can 
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present difficulties in finding cardiac sites with adequate 
electrograms, pacemaker electrode sites adequately distant 
and enough epicardium to accept two large surface, flat 
patch leads. During thoracotomy implantation, for example. 
it is possible to have eight discrete hardware items at a cost 
of more than $20,000. For economy alone, any reduction of 
items and therefore cost will be beneficial. 
Techniques and precautions. Until the introduction of 
advanced devices, the techniques and precautions recom- 
mended by Epstein et al. (1) in this issue of the Journal will 
be important. Pacemaker stimuli must be as small as possi- 
ble, both in actual amplitude and certainly in perception by 
the sensing channel of the AICD. Each time an AICD is 
implanted, consideration should be given to the possibility of 
later pacemaker implantation. The certainty that a pace- 
maker stimulus approximately 0.5 to 1.0 ms in duration can 
be sensed by the AICD should emphasize its relative lack of 
diagnostic specificity and the need for continuing research 
on what constitutes ventricular tachycardia and fibrillation 
for an electronic circuit so that the accuracy of diagnosis can 
be improved. The next generation of devices to manage 
ventricular tachyarrhythmias will very much require and be 
based on such accurate discrimination of cardiac rhythms. If 
AICD diagnosis were adequately discriminatory, maneuvers 
such as those described would be unnecessary. 
Under no circumstances should the implantation of either 
device, alone or together, be performed casually. Their 
interactions are potentially disastrous to hardware and the 
patient. The greatest of care must be exercised to avoid 
untoward device interactions. This issue is as important as 
avoidance of adverse drug interactions and should be con- 
sidered basic to management of AICD implantation, even if 
a pacemaker is never to be implanted in the same patient. 
Epstein and his colleagues are to be commended for their 
efforts to make pacemaker-AICD interaction effective and 
safe. 
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